淋巴瘤患者血清β2-MG、sICAM-1水平变化与临床病理分期及预后相关性分析  

Correlation analysis of serumβ2-MG and sICAM-1 changes with clinicopathological staging and prognosis of lymphoma

作　　者：徐培杰 江慧娟[1] 姚建军[1] 蔡云峰 XU Pei-jie;JIANC Hui-juan;YAO Jian-jun;CAI Yun-feng(Zhejiang Medical Health Group Quzhou Hospital(Zhejiang Quhua Hospital),Quzhou,Zhejiang 324000,China)

机构地区：[1]浙江省医疗健康集团衢州医院(浙江衢化医院),浙江衢州324000

出　　处：《中国卫生检验杂志》2023年第8期976-979,共4页Chinese Journal of Health Laboratory Technology

摘　　要：目的观察淋巴瘤患者血清β2微球蛋白(β2-MG)、可溶性细胞间黏附分子-1(solub leinter cellular adhesion molecule-1,sICAM-1)水平变化,探讨其与临床病理分期及预后相关性。方法选取本院收治的256例淋巴瘤患者作为研究对象,按照AnnArbor临床分期标准分组,其中Ⅰ期52例,Ⅱ期68例,Ⅲ期75例,Ⅳ期61例;根据预后情况分为存活组170例,死亡组86例,同时选取256例同一时间段于本院进行体检的健康体检者作为对照组。采用免疫透射比浊法检测受试者β2-MG水平,采用酶联免疫吸附双抗夹层法检测血清sICAM-1水平。结果淋巴瘤组血清β2-MG、sICAM-1水平均高于对照组(P<0.05);不同临床分期β2-MG、sICAM-1水平差异均有统计学意义(P<0.05),与Ⅰ、Ⅱ期比较,Ⅲ、Ⅳ期β2-MG、sICAM-1水平均升高(P<0.05);与生存组相比较,死亡组患者血清β2-MG、sICAM-1均升高(P<0.05);以淋巴瘤患者血清β2-MG、sICAM-1中位数可分为β2-MG高表达、β2-MG低表达与sICAM-1高表达、sICAM-1低表达,Kaplan-Meier曲线分析结果显示,血清β2-MG、sICAM-1低表达生存率均优于高表达组(P<0.05)。结论淋巴瘤患者血清β2-MG、sICAM-1水平变化与临床病理分期及预后密切相关,有望成为诊断淋巴瘤的有效指标。Objective This paper aims to observe the serumβ2 microglobulin(β2-MG)and soluble intercellular adhesion molecule-1(sICAM-1)changes in patients with lymphoma and explore their correlation with clinicopathological staging and prognosis.Methods A total of 256 lymphoma patients admited to our hospital were selected as the research objects,and they were grouped according to the AnnArbor clinical staging standard.Among them,52 cases were in stage I,68 cases were in stage II,75 cases were in stage II,and 61 cases were in stage IV.According to the prognosis,they were divided into survival group(n=170)and death group(n=86).Another 256 healthy subjects who underwent physical examination in our hospital during the same period were selected as the control group.Immunoturbidimetric method was used to detect theβ2-MG level,and the enzyme-linked immunosorbent double antibody sandwich method was used to detect the serum sICAM-1 level.Results The serum levels ofβ2-MG and sICAM-1 in the lymphoma group were higher than those in the control group(P<0.05),and the differences in the levels ofβ2-MG and sICAM-1 in different clinical stages were statistically significant(P<0.05).Compared with stage I and stage II,β2-MG and sICAM-1 levels in stage II and IV increased(P<0.05).Compared with survival group,the serum levels ofβ2-MG and sICAM-1 in death group were increased(P<0.05).The median of serumβ2-MG and sICAM-1 in lymphoma patients can be divided into high expressionβ2-MG,low expressionβ2-MG,high expression sICAM-1 and low expression sICAM-1.Kaplan-Meier curve analysis results show that the survival rates of serumβ2-MG and sICAM-1 with low expression were better than those with high expression(P<0.05).Conclusion The changes of serumβ2-MG and sICAM-1 levels in patients with lymphoma are closely related to clinicopathological staging and prognosis,and they are expected to become effective indicators for the diagnosis of lymphoma.

关 键 词：淋巴瘤 血清水平 临床病理分期 预后 相关性分析 

分 类 号：R733.4[医药卫生—肿瘤]